Table 2.
Patient and treatment characteristics.
| Characteristic | Treatment subjects | Control subjects | |
|---|---|---|---|
| Plasmapheresis | Immunoadsorption | Non-treatment group | |
| n = 20 | n = 13 | n = 10 | |
| Demographic data | |||
| Age (years), mean (range) |
48 (20–79) |
51 (25–74) |
37 (21–60) |
| Men, n (%) | 10 (50%) | 4 (31%) | 6 (60%) |
| Women, n (%) | 10 (50%) | 9 (69%) | 4 (40%) |
| Demyelinating disease, n | |||
| Multiple sclerosis | 11 | 5 | 10 |
| Optic neuritis | 1 | 2 | 0 |
| NMOSD | 3 | 3 | 0 |
| CIDP | 3 | 2 | 0 |
| GBS | 2 | 1 | 0 |
| Total treatment period (d), mean (range) |
10.3 (8–14) |
9.6 (6–11) |
– |
| Treatment volume (l), mean (range) |
2.8 (2.0–3.5) |
2.0 (2.0–2.0) |
– |
NMOSD Neuromyelitis optica spectrum disorder, CIDP Chronic inflammatory demyelinating polyneuropathy, GBS Guillain–Barré syndrome, d Days, l Liter.